4.7 Article

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL

期刊

LEUKEMIA
卷 36, 期 4, 页码 901-912

出版社

SPRINGERNATURE
DOI: 10.1038/s41375-021-01502-z

关键词

-

资金

  1. Projekt DEAL

向作者/读者索取更多资源

Targeting BCL-2 in B-cell malignancies, including precursor B-cell ALL, is a promising treatment strategy. However, the redundancy of anti-apoptotic BCL-2 family proteins may limit the efficacy of single targeting. Our study reveals the mutual substitution of BCL-XL and MCL-1 in leukemia cells and demonstrates that co-inhibition of BCL-2 and MCL-1 or BCL-XL synergistically induces apoptosis.
Targeting BCL-2, a key regulator of survival in B-cell malignancies including precursor B-cell acute lymphoblastic leukemia, has become a promising treatment strategy. However, given the redundancy of anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, MCL-1), single targeting may not be sufficient. When analyzing the effects of BH3-mimetics selectively targeting BCL-XL and MCL-1 alone or in combination with the BCL-2 inhibitor venetoclax, heterogeneous sensitivity to either of these inhibitors was found in ALL cell lines and in patient-derived xenografts. Interestingly, some venetoclax-resistant leukemias were sensitive to the MCL-1-selective antagonist S63845 and/or BCL-XL-selective A-1331852 suggesting functional mutual substitution. Consequently, co-inhibition of BCL-2 and MCL-1 or BCL-XL resulted in synergistic apoptosis induction. Functional analysis by BH3-profiling and analysis of protein complexes revealed that venetoclax-treated ALL cells are dependent on MCL-1 and BCL-XL, indicating that MCL-1 or BCL-XL provide an Achilles heel in BCL-2-inhibited cells. The effect of combining BCL-2 and MCL-1 inhibition by venetoclax and S63845 was evaluated in vivo and strongly enhanced anti-leukemia activity was found in a pre-clinical patient-derived xenograft model. Our study offers in-depth molecular analysis of mutual substitution of BCL-2 family proteins in acute lymphoblastic leukemia and provides targets for combination treatment in vivo and in ongoing clinical studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据